{
    "clinical_study": {
        "@rank": "134512", 
        "arm_group": [
            {
                "arm_group_label": "AK159 SD 1", 
                "arm_group_type": "Experimental", 
                "description": "Single administration of AK159 dose level 1"
            }, 
            {
                "arm_group_label": "AK159 SD 2", 
                "arm_group_type": "Experimental", 
                "description": "Single administration of AK159 dose level 2"
            }, 
            {
                "arm_group_label": "AK159 SD 3", 
                "arm_group_type": "Experimental", 
                "description": "Single administration of AK159 dose level 3"
            }, 
            {
                "arm_group_label": "AK159 SD 4", 
                "arm_group_type": "Experimental", 
                "description": "Single administration of AK159 dose level 4"
            }, 
            {
                "arm_group_label": "MN-10-T SD", 
                "arm_group_type": "Active Comparator", 
                "description": "Single administration of teriparatide acetate"
            }, 
            {
                "arm_group_label": "AK159 MD 1", 
                "arm_group_type": "Experimental", 
                "description": "Multiple administration of AK159 dose level 1"
            }, 
            {
                "arm_group_label": "AK159 MD 2", 
                "arm_group_type": "Experimental", 
                "description": "Multiple administration of AK159 dose level 2"
            }, 
            {
                "arm_group_label": "AK159 MD 3", 
                "arm_group_type": "Experimental", 
                "description": "Multiple administration of AK159 dose level 3"
            }, 
            {
                "arm_group_label": "AK159 MD 4", 
                "arm_group_type": "Experimental", 
                "description": "Multiple administration of AK159 dose level 4"
            }, 
            {
                "arm_group_label": "MN-10-T MD", 
                "arm_group_type": "Active Comparator", 
                "description": "Multiple administration of MN-10-T"
            }, 
            {
                "arm_group_label": "Placebo MD", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Multiple administration of placebo AK159"
            }
        ], 
        "brief_summary": {
            "textblock": "The objective of this study is to investigate the pharmacokinetics, safety, and tolerability\n      of AK159 administered to healthy postmenopausal women."
        }, 
        "brief_title": "A Phase I Study of AK159 in Healthy Postmenopausal Women", 
        "condition": "Osteoporosis", 
        "condition_browse": {
            "mesh_term": "Osteoporosis"
        }, 
        "detailed_description": {
            "textblock": "This study consists of two parts: Part 1 and Part 2. The Part 1 is a single-center,\n      randomized, 2-way crossover study that investigates the pharmacokinetics, safety, and\n      tolerability of teriparatide after a single dose of AK159 (5 levels) and estimates the\n      relative bioavailability of AK159 with subcutaneous teriparatide acetate in healthy\n      post-menopausal women.\n\n      The Part 2 is a multiple-center, randomized, double-blind, positive- and placebo-controlled,\n      parallel study that compares the pharmacokinetics, bone makers, safety, and tolerability of\n      teriparatide after a weekly doses of AK159 (4 levels) for 6 weeks with placebo and a weekly\n      doses of subcutaneous teriparatide acetate in healthy post-menopausal women."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy postmenopausal ethnic Japanese women\n\n          -  At least 45 years of age at the time consent is obtained\n\n          -  Give voluntary consent in writing with a sufficient understanding of the study.\n\n        Exclusion Criteria:\n\n          -  Clinical abnormality identified in the laboratory tests\n\n          -  Weight < 40.0 kg\n\n          -  Body mass index < 17.5 or >=30.5\n\n          -  History of disease of the kidneys, liver, heart, brain, or other organ that makes\n             them ineligible as subjects\n\n          -  Previously received radiation treatment potentially affecting bone\n\n          -  Clinical abnormality identified in the 12-lead ECGs performed at the study center\n             during the screening period\n\n          -  Systolic blood pressure < 90 mmHg\n\n          -  Serum calcium level exceeding 10.4 mg/dL\n\n          -  History of contact dermatitis or skin disease potentially compromising study\n             evaluation\n\n          -  Used drugs which impact bone metabolism in the 8-week period preceding\n             investigational product administration\n\n          -  Used a bisphosphonate\n\n          -  Used a teriparatide product"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "45 Years"
        }, 
        "enrollment": {
            "#text": "170", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 29, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01935479", 
            "org_study_id": "AK159 I-4"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "AK159 SD 1", 
                    "AK159 SD 2", 
                    "AK159 SD 3", 
                    "AK159 SD 4", 
                    "AK159 MD 1", 
                    "AK159 MD 2", 
                    "AK159 MD 3", 
                    "AK159 MD 4"
                ], 
                "description": "transdermal administration of teriparatide acetate", 
                "intervention_name": "AK159", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "MN-10-T SD", 
                    "MN-10-T MD"
                ], 
                "description": "subcutaneous administration of teriparatide acetate", 
                "intervention_name": "MN-10-T", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo MD", 
                "description": "Placebo AK159", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Teriparatide"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "AK159, teriparatide acetate", 
        "lastchanged_date": "September 2, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Fukuoka", 
                        "country": "Japan"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kumamoto", 
                        "country": "Japan"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sumida", 
                        "country": "Japan"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "11", 
        "other_outcome": {
            "measure": "Residual teriparatide in the patch after application", 
            "safety_issue": "No", 
            "time_frame": "up to 6 weeks after the initial administration"
        }, 
        "overall_contact": {
            "email": "ct-info@om.asahi-kasei.co.jp", 
            "last_name": "Kensaku Goto"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Japan: Pharmaceuticals and Medical Devices Agency"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "February 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Area under the plasma concentration versus time curve (AUC) of teriparatide", 
                "safety_issue": "No", 
                "time_frame": "up to 6 hours after single and repeated administration"
            }, 
            {
                "measure": "Peak Plasma Concentration (Cmax) of teriparatide", 
                "safety_issue": "No", 
                "time_frame": "up to 6 hours after single and repeated administration"
            }, 
            {
                "measure": "Number of subjects with adverse events and Incidence of adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "up to 7 weeks after the initial administration"
            }, 
            {
                "measure": "Change in bone turnover markers from baseline", 
                "safety_issue": "No", 
                "time_frame": "up to 7 weeks after the initial administration"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01935479"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Visual assessment of the application site", 
            "safety_issue": "Yes", 
            "time_frame": "up to 7 weeks after the initial administration"
        }, 
        "source": "Asahi Kasei Pharma Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Asahi Kasei Pharma Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}